Please login to the form below

Not currently logged in
Email:
Password:

Pfizer recalls contaminated IV drugs

Company recalls antibiotics and anti-emetics manufactured by Claris Laboratories due to floating matter and concerns over sterility

Pfizer has recalled batches of the antibiotics metronidazole and ciprofloxacin and the anti-emetic ondansetron after the manufacturer, India-based Claris Laboratories, discovered contamination in the plastic intravenous (IV) bags containing the drugs. All contaminated products are believed to have been made on the same production line.

The FDA website has reported that the white substance floating in a bag of metronidazole was identified by microbiological analysis as Cladosporium mould. Another bag, containing ondansetron, is currently under analysis.

Administering non-sterile products intravenously could result in potentially life-threatening infections, particularly in immunocompromised patients.

The products have only been distributed in the US. Under FDA guidance, Pfizer has recalled all products already distributed and has halted distribution of the remaining products affected by the recall: of the approximately 1.7m bags received from Claris, approximately 80 per cent, or 1.3m, remain in Pfizer's control.

7th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics